Boron neutron capture therapy for oral precancer: proof of principle in an experimental animal model
Article first published online: 15 FEB 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Volume 19, Issue 8, pages 789–795, November 2013
How to Cite
Oral Diseases (2013) 19, 789–795
- Issue published online: 18 OCT 2013
- Article first published online: 15 FEB 2013
- Accepted manuscript online: 25 JAN 2013 11:48AM EST
- Manuscript Accepted: 28 DEC 2012
- Manuscript Revised: 26 DEC 2012
- Manuscript Received: 2 NOV 2012
- Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)
- Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)
- boron neutron capture therapy;
- hamster cheek pouch oral precancer model;
- field cancerization;
- precancerous conditions;
- oral cancer
Field-cancerized tissue can give rise to second primary tumours, causing therapeutic failure. Boron neutron capture therapy (BNCT) is based on biological targeting and would serve to treat undetectable foci of malignant transformation. The aim of this study was to optimize BNCT for the integral treatment for oral cancer, with particular emphasis on the inhibitory effect on tumour development originating in precancerous conditions, and radiotoxicity of different BNCT protocols in a hamster cheek pouch oral precancer model.
Materials and Methods
Groups of cancerized hamsters were locally exposed to single or double (2 or 4 weeks apart) applications of BNCT at different dose levels, mediated by the boron compounds boronophenylalanine (BPA) or BPA and decahydrodecaborate (GB-10) administered jointly. Cancerized, sham-irradiated hamsters served as controls. Clinical status, tumour development from field-cancerized tissue and mucositis were followed for 8 months.
A double application (4 weeks apart) of BNCT mediated by GB-10+ BPA at a total dose of 10 Gy in two 5-Gy doses rendered the best therapeutic advantage (63–100% inhibition of tumour development from field-cancerized tissue), minimizing dose-limiting mucositis.
BNCT can be optimized for the integral treatment for head and neck cancer, considering the implications for field-cancerized tissue.